Kaleido Biosciences Inc expected to post a loss of 57 cents a share - Earnings Preview

Kaleido Biosciences

30/07/2021 14:00

* Kaleido Biosciences Inc  KLDO.OQ   KLDO.O  is expected to show
a fall in quarterly revenue when it reports results on August 2
(estimated). 
* The Bedford, Massachusetts-based company is expected to report
  a 56.0% decrease in revenue to $110 thousand from $250
thousand a year ago, according to the mean estimate from 5
analysts, based on Refinitiv data. 
​* Refinitiv's mean analyst estimate for Kaleido Biosciences Inc
is for a loss of 57 cents per share. For the same quarter last
year, the company reported a loss of 59 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Kaleido
Biosciences Inc is $17​, about 66.5% above​ its last closing
price of $5.69. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  -0.58       -0.59      -0.58     Beat    2.4
 Dec. 31 2020  -0.49       -0.40      -0.56     Missed  -40.6
 Sep. 30 2020  -0.59       -0.63      -0.65     Missed  -2.5​
 Jun. 30 2020  -0.58       -0.59      -0.59     Met     0
 Mar.          -0.64​      -0.64      -0.64     Met     0​
 31​ 2020​                                              
 Dec. 31 2019              -0.34      -0.61     Missed  -80.7​
 Sep. 30 2019  -0.85       -0.89      -0.74     Beat    16.9
 Jun. 30 2019  -0.78       -0.71      -0.83     Missed  -16.2
 This summary was machine generated July 30 at 13:00 GMT.  All
figures in US dollars unless otherwise stated